Nicholas Saraceno is Editor of Pharmaceutical Commerce. He can be reached at [email protected].
In the first part of his Pharma Commerce video interview, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, discusses how from GLP-1 adoption to specialty drugs, behavioral health utilization, and hospital consolidation, multiple forces are reshaping employer-sponsored healthcare costs—and pushing premiums and cost-sharing higher.
In today’s Pharma Pulse, Vanda Pharmaceuticals secures landmark approval for Nereus, while Hoth Therapeutics files dual patents to tackle treatment-induced skin toxicities.
The sustainable packaging company relocates its branded foam production to a more expansive Lansing site, boosting capacity, efficiency, and support for growing demand in the life science market.
In the final part of his Pharma Commerce video interview, Arthur Axelrad, co-founder and CEO of Dispatch Science, explains how outdated, batch-based communication between shippers and carriers is undermining last-mile resilience—and why APIs, cloud platforms, and real-time connectivity are essential to improving transparency, safety, and speed in healthcare logistics.
In today’s Pharma Pulse, the FDA clears new denosumab biosimilars for osteoporosis and cancer-related bone loss, while healthcare leaders grapple with a surge in "nuclear verdicts" driven by shifting public sentiment.
In the final part of her Pharma Commerce video interview, Tina Martinez, vice president and head of global products and solutions at Cencora, explains how streamlining clinical supply services, reducing fragmentation, and piloting data-driven tools like real-time adherence tracking are translating innovation into quantifiable efficiency, visibility, and commercial impact for manufacturers worldwide.
In the second part of his Pharma Commerce video interview, Arthur Axelrad, co-founder and CEO of Dispatch Science, outlines how lapses in digital verification, real-time tracking, and chain-of-custody controls—from pickup through delivery—create security, compliance, and temperature-risk challenges in the final mile of medical logistics.
In the second part of her Pharma Commerce video interview, Tina Martinez, vice president and head of global products and solutions at Cencora, outlines a customer-first approach to partnering with pharmaceutical manufacturers—centered on active listening, early problem validation, and iterative piloting—to co-develop scalable solutions that support late-stage clinical programs through commercial launch.
In the first part of his Pharma Commerce video interview, Arthur Axelrad, co-founder and CEO of Dispatch Science, discusses growing concerns around cargo theft and fraud in healthcare logistics—and how enhanced security features and platform innovation are helping manufacturers protect chain of custody and compliance.
With a planned US launch in early 2026, the approval expands treatment options following strong late-stage trial results.
In the first part of her Pharma Commerce video interview, Tina Martinez, vice president and head of global products and solutions at Cencora, describes how the company uses deep customer relationships and cross-enterprise collaboration to develop new products and solutions that address evolving market dynamics, improve efficiency, and support healthier outcomes.
In today’s Pharma Pulse, Novo Nordisk secures a landmark approval for a weight-loss pill, while Yusen Logistics expands its end-to-end supply chain capabilities across Europe.
The acquisition strengthens Yusen Logistics’ healthcare footprint across Europe, adding specialized transportation, warehousing, digital, and GDP-compliant capabilities to its regional and global network.
As drugmakers experiment with direct-to-patient sales, Thani Jambulingam, PhD, professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business, shares why wholesalers remain indispensable to pharmaceutical distribution—supporting cold chain management, regulatory compliance, billing, and large-scale logistics that manufacturers are not equipped to handle on their own.
In today’s Pharma Pulse, Samsung Biologics enters the US market with a $280 million site acquisition, AstraZeneca secures a multi-billion-dollar cancer deal, and new research identifies occupational drivers of long COVID.
The South Korea–based CDMO acquires its first US manufacturing facility in Rockville, MD, expanding its global footprint and strengthening biologics capacity.
Thani Jambulingam, PhD, professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business, describes why uncertainty around final tariff rules is forcing manufacturers into a wait-and-see position.
In today ’s Pharma Pulse, major pharma players commit to most-favored-nation pricing, as DHL bolsters West Coast logistics for temperature-sensitive drugs.
A $1.5 million investment in its facilities located near Los Angeles International Airport strengthens DHL’s cold chain capacity, supporting pharmaceutical and healthcare shipments while advancing the company’s long-term health logistics strategy for the Americas.
Bill Roth, general manager and managing partner of IntegriChain’s consulting business, previews his new six-part series by outlining how rising payer fragmentation, divergent cash and insurance models, and supply-chain constraints are reshaping brand strategy.
In today’s Pharma Pulse, the Senate advances legislation to block "biotechnology companies of concern," clinical research ties COVID-19 to REM-dominant sleep apnea, and a new analysis reveals an affordability breaking point for employer-sponsored health insurance.
The CDMO’s latest GMP-qualified line strengthens sterile manufacturing scalability.
In a discussion on global trade disruption, Thani Jambulingam, PhD, professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business, explains why pharmaceutical manufacturers must move beyond broad assumptions about tariffs and instead assess trade risk at the individual product level.
In today’s Pharma Pulse, House Republicans block a critical insurance subsidy extension, as new research highlights the oncology benefits of GLP-1s.
The acquisition strengthens CEVA’s global project logistics footprint, adding heavy-lift expertise, specialized engineering talent, and integrated solutions across key regions.
Next year's content looks to carry over the momentum here at Pharmaceutical Commerce.
In a discussion on emerging channel strategies, Bill Roth, general manager and managing partner of IntegriChain’s consulting business, explains why DTP models must extend beyond simple cash-pay offerings—highlighting how packaging innovation, insurance-flow backups, and improved patient compliance could unlock new revenue, streamline access, and better reflect clinical outcomes.
In today’s Pharma Pulse, Novartis and Moderna anchor a domestic manufacturing surge, while AI-driven biomarker discovery and physician well-being reshape the future of clinical care.
The pharmaceutical giant’s new 700,000-square-foot hub aims to onshore production of key medicines and strengthen the US drug supply chain.
CoverMyMeds’ Megan Wetzel unpacks the forces behind rising specialty spend, the real impact of access barriers, and how field reimbursement teams help providers guide patients through today’s fragmented system.
